The participant understands the study and can provide written informed consent;
The participant received surgical treatment of an intermediate to high-risk cutaneous melanoma (T2a/N1, T2b, T3a, T3b, T4a, T4b, N0 or N+, M0 stadium without evidence of disease);
Being able to read and speak Dutch;
Willing to come to the UMCG for practical reasons (visiting the study site);
Willing to continue their regular lifestyle patterns during the study.
You may not be if
Receiving concurrent adjuvant treatment, adjuvant treatment after the study period is allowed.
Having a medical history that may impact study outcomes, such as a diagnosis of diabetes mellitus type 2, heart disease, renal disease, autoimmune disease;
Any clinically significant or unstable medical disorder involving the gut, including celiac disease, inflammatory bowel disease, short-bowel syndrome or acute/chronic pancreatitis;
Having an ileostomy or colostomy, as this greatly impacts bowel function and gut microbial composition;
Use of antibiotics in the 3 months prior participation in the study;
Use of prednisolone or other immunosuppressive medication;
Use of tube feeding or sib-feeding;
Being pregnant or lactating;
Participation in another interventional study at the same time;
Unable or unwilling to comply to study rules.
Clareo Health | Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous Melanoma.
